SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kedersha NL, Miguel NL, Bittner MC, et al. 1990. Vaults II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol 1990;110: 895901.
  • 2
    Rome LH, Kedersha NL, Chugani DC. Unlocking vaults: organelles in search of a function. Trends Cell Biol 1991;1: 4750.
  • 3
    Kickhoefer VA, Siva AC, Kedersha NL, et al. 1999. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999;146: 91728.
  • 4
    Kickhoefer VA, Stephen AG, Harrington L, et al. 1999. Vaults and telomerase share a common subunit, TEP1. J Biol Chem 1999;274: 327127.
  • 5
    Scheffer GL, Wijngaard PLJ, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995;1: 57882.
  • 6
    Izquierdo MA, Scheffer GL, Schroeijers AB, et al. 1998. Vault-related resistance to anticancer drugs determined by the expression of the major vault protein LRP. Cytotechnology 1998;27: 13748.
  • 7
    Moran E, Cleary I, Larkin AM, et al. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. Eur J Cancer 1997;33: 65260.
  • 8
    Verovski VN, Van den Berge DL, Delvaeye MM, et al. Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer 1996;73: 596602.
  • 9
    Versantvoort CHM, Withoff S, Broxterman HJ, et al. Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer 1995;61: 37580.
  • 10
    Wyler B, Shao Y, Schneider E, et al. Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. Br J Haematol 1997;97: 6575.
  • 11
    Kickhoefer VA, Rajavel KS, Scheffer GL, et al. 1998. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998;273: 89714.
  • 12
    Slapak CA, Mizunama N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994;84: 311321.
  • 13
    Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56: 41719.
  • 14
    Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976;17: 56577.
  • 15
    Reid YA, McGuire L, O'Neill K, et al. Cell line cross-contamination of U-937 (correction of U-937). J Leukoc Biol 1995;57: 804.
  • 16
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;16: 5563.
  • 17
    Tanzer LR, Hu Y, Cripe L, et al. A hot-start reverse transcription-polymerase chain reaction protocol that initiates multiple analyses simultaneously. Anal Biochem 1999;273: 30710.
  • 18
    Neter J, Wasserman W, Kutner M. Applied linear statistical models: regression, analysis of variance, and experimental designs, 3rd ed. Homewood, IL: Irwin, 1990: 175.
  • 19
    Kitazono M, Sumizawa T, Takebayashi Y, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999;91: 164753.
  • 20
    Cheng HS, Lam W, Lee ASK, et al. Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol Appl Pharmacol 2000;164: 13442.
  • 21
    Siva AC, Raval-Fernandes S, Stephen AG, et al. Upregulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 2001;92: 195202.
  • 22
    Starling JJ, Shepard RL, Cao J, et al. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 1997;37: 33547.
  • 23
    Chen Y-N, Mickley LA, Schwartz AM, et al. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990;265: 1007380.
  • 24
    Doyle LA, Yang WD, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95: 1566570.
  • 25
    Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59: 455963.
  • 26
    Beketic-Oreskovic L, Duran GE, Chen G, et al. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 1995;87: 1593602.
  • 27
    Bohme M, Buchler M, Muller M, et al. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 1993;333: 1936.
  • 28
    Shepard RL, Law KL, Starling JJ, et al. Modulation of navelbine and mitoxantrone resistance by the P-glycoprotein modulator, LY335979. Presented at the 91st Annual Meeting of the AACR; April 1–5, 2000; San Francisco, CA, USA.